These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16053395)

  • 1. Withdrawal of the parenterally applicable form of thyrostatic drugs in Austria.
    Weissel M
    Thyroid; 2005 Jul; 15(7):746-7. PubMed ID: 16053395
    [No Abstract]   [Full Text] [Related]  

  • 2. Withdrawal of the parenterally applicable form of thyrostatic drugs in Austria.
    Weissel M
    Thyroid; 2005 Oct; 15(10):1203. PubMed ID: 16279858
    [No Abstract]   [Full Text] [Related]  

  • 3. Antithyroid drugs.
    Goichot B; Vinzio S
    N Engl J Med; 2005 May; 352(21):2246-7; author reply 2246-7. PubMed ID: 15917394
    [No Abstract]   [Full Text] [Related]  

  • 4. [Preparation and "in vitro" and "in vivo" evaluation of a transdermal formulation containing methimazole].
    Monti D; Chetoni P; Bonaldi S; Mariotti Bianchi L; Saettone MF
    Boll Chim Farm; 1996 Feb; 135(2):139-41. PubMed ID: 9044563
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal.
    Orunesu E; Bagnasco M; Salmaso C; Altrinetti V; Bernasconi D; Del Monte P; Pesce G; Marugo M; Mela GS
    Eur J Clin Invest; 2004 Mar; 34(3):210-7. PubMed ID: 15025680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology and dosage of thyrostatic drugs].
    Passath A; Leb G; Warnkross H
    Acta Med Austriaca; 1987; 14(3-4):72-4. PubMed ID: 2447738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous methimazole in the treatment of refractory hyperthyroidism.
    Hodak SP; Huang C; Clarke D; Burman KD; Jonklaas J; Janicic-Kharic N
    Thyroid; 2006 Jul; 16(7):691-5. PubMed ID: 16889494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term treatment of thyrotoxicosis with antithyroid drugs].
    Wahlberg P
    Nord Med; 1970 Mar; 83(12):353-6. PubMed ID: 4193207
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe pancytopenia associated with antithyroid drugs in a patient with Graves' disease and chronic renal failure.
    Macia M; Méndez M; Fernández J; Riverol A; Rios
    Clin Nephrol; 1997 Feb; 47(2):129. PubMed ID: 9049463
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there one successful antithyroid regimen for Graves' disease?
    Braverman LE
    Lancet; 1996 Sep; 348(9029):697-8. PubMed ID: 8806285
    [No Abstract]   [Full Text] [Related]  

  • 11. Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment.
    Bianchi G; Solaroli E; Zaccheroni V; Grossi G; Bargossi AM; Melchionda N; Marchesini G
    Horm Metab Res; 1999 Nov; 31(11):620-4. PubMed ID: 10598831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dosage problems in initial thyreostatic therapy of diffuse hyperthyreosis with methylmercaptoimidazole].
    Morgner KD; Gillich KH; Krüskemper HL; Zeidler U
    Med Klin; 1973 Aug; 68(32):1038-41. PubMed ID: 4126297
    [No Abstract]   [Full Text] [Related]  

  • 13. Depigmentation of brown Guinea pig skin by topical application of methimazole.
    Kasraee B
    J Invest Dermatol; 2002 Jan; 118(1):205-7. PubMed ID: 11851896
    [No Abstract]   [Full Text] [Related]  

  • 14. Preparation, characterization, and in vitro release of new transdermal methimazole as alternative to oral delivery.
    Morales ME; Clarés B; López-Viota M; Ruiz MA
    Drug Deliv; 2009 Jan; 16(1):1-10. PubMed ID: 19555302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of chloroquine and methimazole in Graves' disease: a pilot randomized controlled trial.
    Soltani A; Moayyeri A; Azizi F
    Biomed Pharmacother; 2007 May; 61(4):241-3. PubMed ID: 17462854
    [No Abstract]   [Full Text] [Related]  

  • 16. [An apathetic form of thyrotoxicosis].
    Zefirova GS; Makhneva IM; Kochergina II; Plevako VA
    Klin Med (Mosk); 1998; 76(7):48-9. PubMed ID: 9742781
    [No Abstract]   [Full Text] [Related]  

  • 17. Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease.
    Bouma DJ; Kammer H; Greer MA
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1138-42. PubMed ID: 6182155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
    Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C; Duan Y; Wu X
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.